Krishnaswamy Yeleswaram, Chief Development Officer at Rapport Therapeutics, Inc. (RAPP), sold 404 shares at $49.90 ($20K) on 2026-08-19, disclosed to the SEC on 2026-08-20.
Scheduled sale ($20k) by Chief Development Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| RAPP | SELL | 2026-04-14 | $696K | — | Filing → |
| RAPP | SELL | 2026-04-09 | $13K | — | Filing → |
| RAPP | SELL | 2026-03-26 | $607K | — | Filing → |